Glioblastoma
Conditions
Keywords
Glioblastoma
Brief summary
The study pilot evaluate the feasibility of a "5-ALA- PpIX (protoporhyrin IX) mediated per-PDT protocol" in patients with glioblastoma accessible for complete surgical removal of contrast. This treatment will be carried out in addition to the current reference treatment of glioblastoma: maximum resection surgery followed by radiochemotherapy according to the protocol Stupp
Interventions
DEVICE"perPDT"
The protocol requires the realization of specific procedures in addition to the usual care. The per-operative photodynamic therapy ("perPDT") added to surgery for glioblastoma excision. The patient will receive 5-ALA (5- alanine ,GLIOLAN drinkable) 4h before surgery + lighting of the tumor bed by a light source (laser) at the end of resection (Prolonged surgery of 45 minutes).
DRUGGLIOLAN
patient will receive 5-ALA (5- alanine ,GLIOLAN drinkable) 4h before surgery
Sponsors
University Hospital, Lille
Institut National de la Santé Et de la Recherche Médicale, France
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patient male or female ≥18 years 2. General status (WHO) of Performance status 0, 1 or 2 3. Probable glioblastoma according to clinical and radiological criteria, 4. whose surgical indication was given in Multidisciplinary consultation meeting (RCP) of neurooncology, 5. Decision to treat the patient as part of the Clinical trial also taken in neuro-oncology RCP ("Multidisciplinary consultation meeting") 6. Patient operable on the basis of absence of cardiopulmonary disease history; a complete medical check-up sufficient to insure a post-operative state with normal daily life 7. Clinical neuro-oncological monitoring and long-term MRI scheduled at the hospital CHRU of Lille, center of reference of the region 8. Patient able to understand and sign voluntarily Informed consent 9. Patient able to adhere to the visit's calendar of the study and other imperatives of the protocol 10. Women of child-bearing potential should benefit of an effective contraception 11. For patients receiving hepatotoxic therapy in the long term, this treatment must be suspended during the 24h after taking 5-ALA 12. Patient assigned to an heath insurance
Exclusion criteria
1. Contraindications to 5-ALA (Gliolan®) and to per-operative PhotoDynamic Therapy "perPDT": 2. Contraindications to 5-ALA * Porphyria * Taking photosensitizer treatment * Severe renal or hepatic impairment * Bilirubin\> 1.5 x maximum level, Alkaline Phosphatases and transaminases (ASAT)\> 2.5 x Maximum. rates * Creatinine clearance \<30 mL / min; * Non-compliance with the rules of prevention of the transient risk of cutaneous photosensitization 3. Contraindications to surgery 4. Contraindications to magnetic resonance imaging (MRI) 5. Treatment with an experimental drug within 30 Days prior to the start of the study 6. Clinical follow-up impossible to perform for psychological, familial, social or geographical reasons, 7. Legal incapacity (persons deprived of their liberty or Guardianship or guardianship), 8. Pregnant or nursing women 9. Refusal to participate or sign the consent of the study 10. Soy allergy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Patients having the full "PerPDT" treatment with unacceptable and unexpected toxicities (grade ≥ 3) graded According to NCI CTC Version 4.0 | From the intake of Gliolan (5-Ala) until 1 month post "perPDT" | In particular, the following complications will be investigated: severe infection, new neurological deficit responsible for severe disability, status epilepticus, deaths during the postoperative period. Target: At least 6/10 patients who benefited of complete "PerPDT" and without unacceptable and unexpected toxicities |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival (PFS) | From the Date of diagnosis of glioblastoma until the date of Relapse defined, assessed up to 24 months | Determined according to international RANO criteria |
| Overall Survival (OS) | From the date of Diagnosis of glioblastoma until the date of death, assessed up to 24 months | Determined according to international RANO criteria |
| Response to treatment | From the date of perPDT until relapse/death, assessed up to 24 months | Evaluated by MRI every 3 months |
| Incidence of "per PDT" treatment-emergent Adverse Events | From the beginning of treatment with perPDT up to relapsing/death, assessed up to 24 months | Collection of all Adverse events (AEs and SAEs) (according to NCI-CTC V4.0) and reviewing by an Independent Safety Monitoring Board. |
| Quality of Life Questionnaire -C30 ( QLQ-C30) | Every 3 months from the signature of Consent form until relapse/death, assessed up to 24 months | The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items. |
| Quality of Life Questionnaire - Brain Cancer Module (QLQ-BN20) | Every 3 months from the signature of Consent form until relapse/death, assessed up to 24 months | Measuring the health-related quality of life in patients with brain cancer |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORNicolas Reyns, MD, PhD
University Hospital, Lille
Outcome results
None listed